RubrYc Therapeutics, Inc., a San Ramon, CA-based biotherapeutics discovery company, closed a $10m Series A equity financing.
The round was led by Third Point Ventures, with participation from Paladin Capital Group and Vital Venture Capital.
The company intends to use the funds to continue to build its antibody discovery platform, proprietary pipeline of therapeutic candidates, and initiate new pharmaceutical partnerships.
Founded in 2017 and led by Dr. Isaac Bright, CEO, and Bill Colston, CEO of HealthTell and Executive Chairman, RubrYc Therapeutics is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., the company is training algorithms that inform improved decision-making throughout drug discovery. RubrYc will be collaborating with biotechnology companies in early drug discovery and developing its own molecules.